Acrivon Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Acrivon Therapeutics, Inc. (ACRV) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.53 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-12
- Acrivon Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $1.51, a 71.56% decline year-over-year.
- Acrivon Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $5.31, a 4.32% decline year-over-year.
- Acrivon Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $5.55, a 69.97% decline year-over-year.
- Acrivon Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $18.48.
- Acrivon Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $4.64, a 20.82% decline from fiscal 2024.
- Acrivon Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $5.86, a 43.82% decline from fiscal 2023.
- Acrivon Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $10.43, a 34.75% increase from fiscal 2022.
- Acrivon Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $7.74.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.53 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $1.51 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $4.64 10-K · filed 2026-03-19 | |||
| 2025-09-30 | $4.94 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $4.96 10-Q · filed 2025-08-13 | |||
| 2025-03-31 | $5.31 10-Q · filed 2025-05-14 | |||
| 2024-12-31 | $5.86 10-K · filed 2025-03-27 | |||
| 2024-09-30 | $5.75 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $5.67 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $5.55 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $10.43 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $12.11 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $14.45 10-Q · filed 2023-08-11 | |||
| 2023-03-31 | $18.48 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $7.74 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rallybio Corp (RLYB) | United States | $0.089B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |